Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.58 |
| ▸ | DPP4 | P27487 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.58 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.58 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.58 |
| ▸ | GAPDH | P04406 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | STAT6 | P42226 | 1/20 | 0.58 |
| ▸ | PI4KA | P42356 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6673147 | 1.00 | LMNA (0.63) | LMNATP53NT5EHIF1AADORA2A | |
| SCHEMBL11805362 | 0.90 | LMNA (0.66) | LMNATP53NT5EHIF1AADORA2A | |
| Xanthosine SCHEMBL8665102 | 0.89 | LMNA (0.65) | LMNATP53NT5EHIF1AADORA2A | |
| Xanthosine SCHEMBL188120 | 0.89 | LMNA (0.65) | LMNATP53NT5EHIF1AADORA2A | |
| Xanthosine SCHEMBL6676995 | 0.89 | LMNA (0.65) | LMNATP53NT5EHIF1AADORA2A | |
| Xanthosine SCHEMBL11523732 | 0.89 | LMNA (0.65) | LMNATP53NT5EHIF1AADORA2A | |
| Xanthosine SCHEMBL5352244 | 0.88 | LMNA (0.63) | LMNATP53NT5EHIF1AADORA2A | |
| Thioguanosine SCHEMBL23927999 | 0.86 | CYP2C19 (0.73) | LMNANT5EHIF1AADORA2AADORA2B | |
| Thioguanosine SCHEMBL608145 | 0.86 | CYP2C19 (0.73) | LMNANT5EHIF1AADORA2AADORA2B | |
| Thioguanosine SCHEMBL4083505 | 0.86 | CYP2C19 (0.73) | LMNANT5EHIF1AADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485171-B2 | Methods of disease activity profiling for personalized therapy management | PROMETHEUS LABORATORIES INC. (US) | 2025-12-02 | — | — | US | disclosed |
| CN-117460532-A | Medicine for treating and/or preventing cancer | 东丽株式会社 | 2024-01-26 | — | — | CN | disclosed |
| US-20230078652-A1 | METHODS FOR PREDICTION OF ANTI-TNF ALPHA DRUG LEVELS AND AUTOANTIBODY FORMATION | PROMETHEUS LABORATORIES INC (US) | 2023-03-16 | — | — | US | disclosed |
| US-11435347-B2 | Methods for prediction of anti-TNF α drug levels and autoantibody formation | PROMETHEUS LABORATORIES INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20220096629-A1 | METHODS OF DISEASE ACTIVITY PROFILING FOR PERSONALIZED THERAPY MANAGEMENT | PROMETHEUS LABORATORIES INC. | 2022-03-31 | — | — | US | disclosed |
| US-11160863-B2 | Methods of disease activity profiling for personalized therapy management | PROMETHEUS LABORATORIES INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-10794906-B2 | Assays for detecting neutralizing autoantibodies to biologic therapy | PROMETHEUS BIOSCIENCES, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200158725-A1 | METHODS FOR PREDICTION OF ANTI-TNF ALPHA DRUG LEVELS AND AUTOANTIBODY FORMATION | PROMETHEUS LABORATORIES INC. | 2020-05-21 | — | — | US | disclosed |
| EP-2494352-B1 | ASSAYS FOR THE DETECTION OF ANTI-TNF DRUGS AND AUTOANTIBODIES | PROMETHEUS BIOSCIENCES INC (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10571467-B2 | Methods for prediction of anti-TNFα drug levels and autoantibody formation | Prometheus Biosiences, Inc. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-1115403-B1 | METHOD FOR OPTIMIZING THE USE OF 6-MERCAPTOPURINE IN THE TREATMENT OF IMMUNE-MEDIATED GASTROINTESTINAL DISORDERS | CHU SAINTE JUSTINE (CA) | 2005-12-14 | — | — | EP | disclosed |
| US-20050234078-A1 | Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders | HOPITAL SAINTE-JUSTINE (CA) | 2005-10-20 | — | — | US | disclosed |
| US-20050202483-A1 | ITPase gene polymorphisms associated with adverse durg reactions to azathioprine therapy | GUY'S AND ST. THOMAS' NHS FOUNDATION TRUST (GB) | 2005-09-15 | — | — | US | disclosed |
| US-20040097527-A1 | Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders | HOPITAL SAINTE-JUSTINE | 2004-05-20 | — | — | US | disclosed |
| US-6680302-B2 | ADMINISTERING A 6- MERCAPTOPURINE DRUG TO A PATIENT HAVING IMMUNE-MEDIATED GASTROINTESTINAL DISORDER AND DETERMINING A LEVEL OF 6-THIOGUANINE IN THE PATIENT | HOSPITAL SAINTE-JUSTINE (CA) | 2004-01-20 | — | — | US | disclosed |
| US-20020082239-A1 | Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders | HOPITAL-SAINTE-JUSTINE (CA) | 2002-06-27 | — | — | US | disclosed |
| US-6355623-B2 | DETERMINING THE LEVEL OF 6-THIOGUANINE METABOLITE WHEREIN A LEVEL OF 6-THIOGUANINE LESS THAN ABOUT 230 PMOL PER 8 X 108 RED BLOOD CELLS INDICATES A DRUG INCREASE; A LEVEL OF 400PMOL INDICATES A DECREASE; NONTOXIC | HOPITAL-SAINTE-JUSTINE (CA) | 2002-03-12 | — | — | US | disclosed |
| EP-1115403-A1 | OPTIMIZED USE OF 6-MERCAPTOPURINE DRUG IN THE TREATMENT OF IMMUNE-MEDIATED GASTROINTESTINAL DISORDERS | Hospital Sainte-Justine (CA) | 2001-07-18 | — | — | EP | disclosed |
| US-20010006970-A1 | Determining the level of 6-thioguanine metabolite wherein a level of 6-thioguanine less than about 230 pmol per 8 x 108 red blood cells indicates a drug increase; a level of 400pmol indicates a decrease; nontoxic | HOPITAL SAINTE-JUSTINE | 2001-07-05 | — | — | US | disclosed |
| WO-2000016780-A1 | OPTIMIZED USE OF 6-MERCAPTOPURINE DRUG IN THE TREATMENT OF IMMUNE-MEDIATED GASTROINTESTINAL DISORDERS | HOPITAL SAINTE-JUSTINE (CA) | 2000-03-30 | — | — | WO | disclosed |